Comparative Pharmacology
Head-to-head clinical analysis: HYDROXOMIN versus RUBIVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXOMIN versus RUBIVITE.
HYDROXOMIN vs RUBIVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxocobalamin is a synthetic form of vitamin B12 that acts as a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis. It also acts as a direct scavenger of cyanide ions by binding to them to form cyanocobalamin, which is excreted renally.
Hydroxocobalamin is a synthetic form of vitamin B12 that acts as a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, erythrocyte maturation, and neurological function. In cyanide poisoning, it binds cyanide ions to form nontoxic cyanocobalamin, which is excreted renally.
100 mg intramuscularly or deep subcutaneously three times a week.
1000 mcg intramuscularly or deep subcutaneous injection once daily for 5-7 days, then 100-1000 mcg monthly for maintenance.
None Documented
None Documented
Terminal elimination half-life approximately 4-6 hours; may extend to 8-12 hours in moderate to severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 24-48 hours in severe impairment)
Primarily renal (80-90% unchanged) with minor biliary/fecal elimination (5-10%); total clearance ~150 mL/min.
Primarily renal; ~50-80% of absorbed dose excreted unchanged in urine within 24 hours; biliary/fecal excretion accounts for minor fraction (<10%)
Category C
Category C
Vitamin B12 Supplement
Vitamin B12 Supplement